OTCMKTS:GNNSF Genscript Biotech (GNNSF) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free GNNSF Stock Alerts C$1.40 0.00 (0.00%) (As of 05/24/2024 ET) Add Compare Share Share Today's RangeC$1.40▼C$1.4050-Day RangeC$1.40▼C$2.0552-Week RangeC$1.40▼C$3.20VolumeN/AAverage Volume72,161 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Genscript Biotech alerts: Email Address Ad Porter & CompanyMusk, Bezos, and Gates All On Board… Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.To get all the details of this controversial tech – click here now. About Genscript Biotech Stock (OTCMKTS:GNNSF)Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation. The Biologics Development Services segment offers end-to-end service offerings to biologics development and manufacturing for biopharma and biotech partners, as well as therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor CAR-T cell therapies for the treatment of liquid and solid tumors. It has a strategic partnership with Multiply Labs for automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.Read More GNNSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNNSF Stock News HeadlinesMay 25 at 3:47 AM | seekingalpha.comGNNSF Genscript Biotech CorporationMay 13, 2024 | prnewswire.comGenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic ApplicationsApril 25, 2024 | businesswire.comMultiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy ManufacturingApril 24, 2024 | finance.yahoo.comGenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future BlueprintApril 23, 2024 | prnewswire.comMultiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy ManufacturingApril 15, 2024 | prnewswire.comGenScript Biotech officially joins SBTi to fulfill its sustainability commitmentMarch 26, 2024 | finance.yahoo.comGenScript Biotech Receives EcoVadis Bronze Medal for Outstanding Sustainability PerformanceMarch 12, 2024 | prnewswire.comGenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%March 11, 2024 | msn.comGenscript Biotech GAAP EPS of -$4.53, revenue of $839.5M misses by $460.5MMarch 8, 2024 | finance.yahoo.comDr. David Liu Joins GenScript's Scientific Advisory Board to Guide Company's Innovation StrategyMarch 6, 2024 | finance.yahoo.comImmunotherapy Pioneer Carl H. June, MD, Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy in Advancing Cell and Gene Therapy BreakthroughsFebruary 25, 2024 | seekingalpha.comWeek In Review: AlphaGen And ArtBio Form China-U.S. Radioligand PartnershipFebruary 5, 2024 | finance.yahoo.comGenScript Announces Its Inaugural Life Science Research Grant ProjectJanuary 8, 2024 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)January 4, 2024 | finance.yahoo.comGenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT IndustryJanuary 4, 2024 | finance.yahoo.comGenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare SectorDecember 24, 2023 | finance.yahoo.comFDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene TherapyDecember 19, 2023 | nasdaq.comGenscript Biotech Corporation - Class H (GNNSF)December 14, 2023 | finance.yahoo.comGenScript to Host Biotech Global Forum 2024 during 42nd Annual J.P. Morgan Healthcare ConferenceDecember 1, 2023 | finance.yahoo.comGenScript Named a BioSpace 2024 Best Place to WorkNovember 10, 2023 | businesswire.comGenScript ProBio Signs Viral Vector Manufacturing MOU With Curocell for Next-Generation CAR-T TherapySeptember 18, 2023 | finance.yahoo.comGenScript Expands Range of Reagent Services, Adding Circular RNA and Lipid Nanoparticles FormulationAugust 10, 2023 | msn.comGenScript Biotech expands peptide production at Zhenjiang facilityAugust 9, 2023 | finance.yahoo.comGenScript Biotech and T-MAXIMUM Biotech Form Strategic Alliance on cGMP sgRNAAugust 8, 2023 | finance.yahoo.comGenScript Expands Peptide Production Capabilities to Include Neoantigen Peptides and APIsSee More Headlines Receive GNNSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genscript Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:GNNSF CUSIPN/A CIKN/A Webwww.genscript.com Phone862558897288FaxN/AEmployees6,937Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Jiange Meng (Age 56)Executive Chairman Comp: $693kMs. Weihui Shao (Age 44)CEO & COO Ms. Ye Wang M.S. (Age 56)Co-Founder, President & Executive Director Comp: $461kMr. Shiniu Wei (Age 45)Chief Financial Officer Dr. Fangliang Zhang EMBA (Age 59)Ph.D., co-founder & Executive Director Comp: $271kDr. Li Zhu Ph.D. (Age 74)Chief Strategy Officer & Executive Director Comp: $280kMs. Wai Ling Wong A.C.I.S. (Age 44)A.C.S., Company Secretary More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors GNNSF Stock Analysis - Frequently Asked Questions How have GNNSF shares performed in 2024? Genscript Biotech's stock was trading at C$2.44 at the start of the year. Since then, GNNSF stock has decreased by 42.6% and is now trading at C$1.40. View the best growth stocks for 2024 here. Are investors shorting Genscript Biotech? Genscript Biotech saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 10,662,000 shares, an increase of 118.8% from the April 15th total of 4,873,900 shares. Based on an average daily volume of 8,600 shares, the short-interest ratio is presently 1,239.8 days. View Genscript Biotech's Short Interest. How do I buy shares of Genscript Biotech? Shares of GNNSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GNNSF) was last updated on 5/26/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s PRIME is Set to Shock the WorldInvestorPlaceShocking $16T Elon Musk Crypto LeakCrypto 101 MediaJust $9 for a Year of Winning Market InsightsBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsNew Options need New Trading StrategiesNetpicks$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe Presidential candidate you should REALLY be worried aboutStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genscript Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.